We congratulate Dr. Touchette and colleagues for their economic analysis of alvimopan. 1 We wanted to clarify the questions and concerns they raised about our previous economic analysis of alvimopan. 2 They expressed concern about inconsistencies in our patient numbers. Our total number of patients represented pooled data from all patients in the modified intent-to-treat populations from four phase III North American efficacy trials who underwent bowel resection and received placebo or alvimopan 12 mg (labeled indication and dose). [3] [4] [5] [6] This population was described previously by Dr. Wolff and colleagues 7 and is also noted in the sponsor's United States Food and Drug Administration (FDA) briefing document used for the alvimopan advisory committee meeting (Table  12. 3.1; studies 14CL302, 14CL308, 14CL313, and 14CL314). 8 We did not include data from patients who received alvimopan 6 mg or from patients who underwent total abdominal hysterectomy (nonapproved dose and indication). However, these patients were included in the first three phase III trials; as such, it appears that the data inputs used by Dr. Touchette and colleagues included data from these patients in addition to patients who underwent bowel resection. Furthermore, they did not include the largest and most recently published phase III efficacy study that evaluated alvimopan 12 mg only in patients who underwent bowel resection (labeled dose and indication). 6 This study was included in our economic evaluation. 2 In North America, hospital discharge is closely linked to gastrointestinal recovery. Therefore, treatments that accelerate gastrointestinal recovery may shorten hospital length of stay. Review of the European phase III efficacy study showed that hospital length of stay was not linked to gastrointestinal recovery, 9 likely due to regional variation in practice patterns along with other differences that may impact decisions on hospital discharge. Therefore, we did not include these data in our economic analysis nor was it included in the FDA's evaluation of the drug for hospital discharge end points.
We used two sources to estimate total hospital costs for the pooled data in our analysis (dayspecific hospital cost estimates for bowel resection procedures from Premier's Perspective Comparative Database and costs published in the 2007 U.S. Census Bureau statistical abstract for 2004, converted to 2007 dollars). 2 Despite using different data inputs, different patient data, and a different analytic approach, Dr. Touchette and colleagues' overall results were consistent with the conclusions from our analysis. Furthermore, these results are consistent with results of other 
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large database or institutional analyses of alvimopan. [10] [11] [12] Overall, the results of these analyses suggest that use of alvimopan as indicated may be cost-beneficial provided that length of stay is reduced.
